A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression.
Description
Frontiers in Psychiatry; 07/04/2023(AN 164773665); ISSN: 16640640Complementary Index